To objective of this protocol is threefold.1. To investigate transdiagnostic cognitive deficits across a diversity of different psychiatric disorders.2. To link cognitive deficits with symptom-dimensions, EEG, cortisol, genetic and other blood…
ID
Source
Brief title
Condition
- Cognitive and attention disorders and disturbances
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Cognitive functioning
Secondary outcome
- Self-report questionnaires
- Blood markers
- Electro-encephalogram (EEG)
- Hair cortisol analysis
Background summary
The majority of patients with a psychiatric disorder such as major depressive
disorder, schizophrenia or obsessive-compulsive disorder, suffers from
cognitive dysfunction (e.g. in attention, memory, and planning ability).
Cognitive dysfunction can play a major role in functional capacity and
independence in everyday activities. Cognitive dysfunction is, therefore, a
poorly controlled and highly relevant dimension of psychiatric disorders that
cuts across traditional diagnostic boundaries, and improved treatment should be
a major goal in efforts to enhance quality of life for patients.
Study objective
To objective of this protocol is threefold.
1. To investigate transdiagnostic cognitive deficits across a diversity of
different psychiatric disorders.
2. To link cognitive deficits with symptom-dimensions, EEG, cortisol, genetic
and other blood marker variations in psychiatric patients.
3. To investigate the longitudinal course of cognitive deficits in psychiatric
patients in relationship to symptom-dimensions and biological parameters.
Study design
Longitudinal cohort study
Study burden and risks
There are minimal risks associated with participation. Extent of the burden is
an assessment of 3 hours at baseline and 1 year follow up. Benefits are that
the treating physician and patient can receive a report of the results of the
cognitive testbattery and clinical questionnaires, that could be used in the
treatment plan.
Meibergdreef 5
Amsterdam 1105AZ
NL
Meibergdreef 5
Amsterdam 1105AZ
NL
Listed location countries
Age
Inclusion criteria
1. Ability to give informed consent
2. Where participants are of legal childhood age, consent will also be obtained from one of the participant*s parents. Both the parent and participant will be required to sign the consent form in such a case. It will be the investigator*s responsibility to determine whether a participant of legal childhood age has the capacity to consent to the study.
3. Age 14 - 75 years.
4. DSM-IV-TR diagnosis on Axis I.
5. Fluent in Dutch.
6. Clinically stable
Exclusion criteria
1. High risk of suicide
2. Unstable medical disorder
3. Premorbid IQ < 70
4. History of a clinically significant abnormality of the neurological system (including dementia and other cognitive disorders or significant head injury) or any history of seizure (excluding febrile seizure).
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
In other registers
| Register | ID |
|---|---|
| CCMO | NL55751.018.15 |
| OMON | NL-OMON26462 |